For research and educational purposes only. Not intended for human consumption.
Semax
Well Researched- •2025 Alzheimer's disease model - reduced amyloid
- •Amyloid-β fibril inhibition confirmed
- •ADHD attention model data published
Synthetic ACTH Analog | Cognitive Enhancement Peptide
Overview
What is Semax?
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4-10, extensively studied for its nootropic, neuroprotective, and neurorestorative properties. Originally developed in Russia for stroke recovery, this brain-targeted peptide rapidly increases BDNF levels via CREB pathway and modulates dopaminergic and serotonergic systems. Recent 2024-2025 research demonstrates efficacy in Alzheimer's disease models, reducing amyloid inclusions and improving cognitive function, with emerging applications in ADHD and neurodegenerative conditions.
Key Benefits
Rapid brain delivery, extensive clinical research, easy self-administration, excellent bioavailability to brain regions, demonstrated amyloid-β fibril inhibition, enhanced attention and impulse control, and BDNF upregulation via CREB transcription factor.
Mechanism of Action
Direct transport through olfactory epithelium and trigeminal nerves, bypassing blood-brain barrier for enhanced CNS penetration. Enhances neurotrophin transcription (BDNF via CREB), modulates dopaminergic/noradrenergic systems in prefrontal cortex, inhibits Aβ fibril formation, and targets μ-opioid receptor (Oprm1) for neuroprotection.
Molecular Information
Pharmacokinetics
Research Indications
Memory Enhancement
Improved short-term and working memory performance in fatigued individuals and healthy subjects.
Attention and Focus
Enhanced sustained attention during demanding cognitive tasks and prolonged work periods.
Learning Acceleration
Faster acquisition of new information and improved retention in educational settings.
Research Protocols
Disclaimer: Semax is approved in Russia for various neurological conditions. These protocols are for research purposes. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cognitive enhancement (healthy adults) | 300-600mcg | 1-2 times daily | Intranasal spray/drops |
| Learning and memory support | 600-900mcg | 2-3 times daily during study periods | Intranasal spray/drops |
| Recovery from brain injury | 900-1500mcg | 2-3 times daily | Intranasal (clinical supervision) |
| Anti-fatigue cognitive support | 400-800mcg | Single morning dose | Intranasal spray |
Timing: Morning administration optimizes cognitive benefits throughout the day while avoiding evening alertness that could impact sleep.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Semax nasal formulations come pre-mixed as 0.1% or 1% solutions
For research use, lyophilized powder can be reconstituted with sterile saline
Use preservative-free saline for nasal administration to avoid irritation
Calculate concentration based on desired mcg per spray or drop
Store reconstituted solution refrigerated and use within recommended timeframe
Always use sterile technique when preparing nasal formulations
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Clear, Colorless Solution
Semax nasal solution should be transparent without particles or cloudiness.
Proper Concentration Labeling
Clearly marked as 0.1% or 1% Semax with accurate mcg per spray information.
Cold Chain Shipping
Nasal formulations should arrive with cold packs and require immediate refrigeration.
Sterile Packaging
Sealed nasal spray bottles or ampoules with sterility assurance.
Nasal Irritation Potential
Some mild nasal discomfort possible - discontinue if severe irritation occurs.
Crystallization or Precipitation
Any visible crystals or particles indicate degradation or contamination.
What to Expect
- •Days 1-3: Initial cognitive clarity and focus enhancement, possible mild nasal sensation
- •Week 1: Improved attention span and mental stamina during demanding tasks
- •Week 2-3: Enhanced memory consolidation and learning capacity, stable mood effects
- •Week 4: Peak cognitive benefits with improved stress resilience and mental flexibility
- •Post-cycle: Gradual return to baseline over 3-7 days, some benefits may persist
Side Effects & Safety
Side Effects
- •Start with lowest effective dose (300mcg) to assess individual response
- •Avoid concurrent use with other intranasal medications that cause vasoconstriction
- •Monitor for any signs of nasal irritation, bleeding, or persistent discomfort
- •Do not exceed 4-week continuous use periods without medical supervision
- •Potential to enhance effects of stimulants - reduce other stimulant doses accordingly
When to Stop
- •Persistent nasal irritation or bleeding
- •Severe headaches
- •Sleep disturbances
- •Mood changes
- •Consult healthcare provider
References
6 StudiesStroke Recovery Clinical Trial
Human | 110 patients | Semax + conventional therapy | Ischemic stroke recovery
Patients recovering from ischemic stroke who received Semax showed increased BDNF levels correlated with early rehabilitation and accelerated restoration of brain functions.
fMRI Default Mode Network Study
Human | 24 participants | Single dose intranasal | Brain imaging analysis
Healthy middle-aged participants showed increased fMRI default mode network activity relative to placebo, indicating enhanced neural connectivity.
Alzheimer's Disease Model (2025)
APP/PS1 mice | Intranasal administration | Improved cognition, reduced amyloid
In Alzheimer's disease mouse models, Semax improved cognitive functions (open field, novel object recognition, Barnes maze tests) and significantly reduced amyloid inclusions in cortex and hippocampus.
Quick Start Guide
Research Disclaimer
Semax is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Semax must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Semax for any purpose. Consult qualified professionals for any research applications.